Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0038389992
Tue, 30.08.2022
BB BIOTECH AG
Market commentary, August 30, 2022
Dr. Daniel Koller, Head Investment Management Team, BB Biotech at Bellevue Asset Management
Moderna was just the beginning
RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years.
Alnylam, a stock in BB Biotech's portfolio, [ … ]
Tue, 30.08.2022
BB BIOTECH AG
Market commentary, August 30, 2022
Dr. Daniel Koller, Head Investment Management Team, BB Biotech at Bellevue Asset Management
Moderna was just the beginning
RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years.
Alnylam, a stock in BB Biotech's portfolio, [ … ]
Fri, 22.07.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
July 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss for the [ … ]
Fri, 22.07.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
July 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss for the [ … ]
Fri, 22.07.2022
BB BIOTECH AG
Media release as at July 22, 2022
Interim report of BB Biotech AG as at June 30, 2022
First signs of increased M&A activity due to attractive valuations
The second quarter was distinguished by a difficult macroeconomic environment and, particularly, by stubbornly high inflation. The broad market corrections that began earlier in the year con [ … ]
Fri, 22.07.2022
BB BIOTECH AG
Media release as at July 22, 2022
Interim report of BB Biotech AG as at June 30, 2022
First signs of increased M&A activity due to attractive valuations
The second quarter was distinguished by a difficult macroeconomic environment and, particularly, by stubbornly high inflation. The broad market corrections that began earlier in the year con [ … ]
Tue, 24.05.2022
BB BIOTECH AG
Market commentary, 24 May 2022
Dr. Daniel Koller, Head Investment Team BB Biotech at Bellevue Asset Management
Disruptive technologies are changing an entire industry
The biotech industry is increasingly applying next-generation therapeutic approaches to develop drugs for diseases and conditions with larger populations of patients. The sales pot [ … ]
Fri, 22.04.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
April 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2022, which covers the results of its business activities for the first three months of 2022.
Based on the consolidated accounts of BB Biot [ … ]
Fri, 22.04.2022
BB BIOTECH AG
Media release as at April 22, 2022
Interim report of BB Biotech AG as at March 31, 2022
Increased investment level balanced by established core holdings
Markets were subject to large swings in valuation during the first quarter of 2022. A broad sell-off during the first two months was followed by a strong rebound in March. The biotechnology sect [ … ]
Tue, 12.04.2022
BB BIOTECH AG
Media Release of April 12, 2022
BB Biotech AG concludes its share buyback program and launches a new buyback program
Yesterday, April 11, 2022, BB Biotech AG concluded the share buyback program it had initiated on April 12, 2019. During this period no registered shares were repurchased via a second trading line.
The Board of Directors passed a m [ … ]